Search Results

You are looking at 1 - 10 of 41 items for :

  • risperidone x
Clear All
Open access

Ana Filipce, Zorica Naumovska, Aleksandra Kapedanovska Nestorovska, Zoran Sterjev, Katerina Brezovska, Jasmina Tonic-Ribarska, Aleksandra Grozdanova, Ljubica Suturkova and Marija Raleva

REFERENCES 1. Gardner ER, Figg WD, Sparreboom A., Pharmacogenomics of the Human ATP-Binding Cassette Transporter ABCG2.Current Pharmacogenomics 11/2006; 4(4): 331–344. 2. Aichhorn W, Weiss U, Marksteiner J, Kemmler G, Walch T, Zernig G, Stelzig-Schoeler R, Stuppaeck C, Geretsegger C. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol. 2005 Jul; 19(4): 395–401. Laysen JE et al., 1988–9. 3. Rafaniello C, Sessa M, Bernardi FF, Pozzi M, Cheli S, Cattaneo D, Baldelli S, Molteni M, Bernardini R, Rossi F, Clementi E

Open access

Khalid M. El-Say, Tarek A. Ahmed, Maged F. Abdelbary, Bahaa E. Ali, Bader M. Aljaeid and Ahmed S. Zidan

, Int. J. Pharm. 404 (2011) 1-9; DOI: 10.1016/j.ijpharm.2010.11.001. 4. D . L. Munday, A comparison of the dissolution characteristics of theophylline from film coated granules and mini-tablets, Drug Dev. Ind. Pharm. 20 (1994) 2369-2379; DOI: 10.3109/03639049409042643. 5. M. L. Huang, A. Van Peer, R. Woestenborghs, R. De Coster, J. Heykants, A. A. Jansen, Z. Zylicz, H. W. Visscher and J. H. Jonkman, Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects, Clin. Pharmacol. Ther. 54

Open access

Fugen Gu, Weina Ma, Gendalai Meng, Chunzhi Wu and Yi Wang

References 1. T. Cabaleiro, D. Ochoa, R. López-Rodríguez, M. Román, J. Novalbos, C. Ayuso and F. Abad-Santos, Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers, Hum. Psychopharmacol. 29 (2014) 459-469; DOI: 10.1002/hup.2420. 2. J. L. Sun, Q. X. Chen, S. Tian, F. R. Meng, Y. Lv and G. H. Du, Absorption of risperidone polymorphs administrated orally in rats, Chin. Pharm. J. 46 (2011) 1919-1922. 3. T. K. Vyas, A. Shahiwala, S. Marathe and A. Misra

Open access

Alexander Kiss

. Fujimura M, Hashimoto K, Yamagami K. The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain: comparison with haloperidol, clozapine and risperidone. Life Sci 67, 2865–2872, 2000. Hallbeck M. Dynorphin mRNA-expressing neurons in the rat paraventricular hypothalamic nucleus project to the spinal cord. Neurosci Lett 285, 161–164 2000. Hallbeck M, Larhammar D, Blomqvist A. Neuropeptide expression in rat paraventricular hypothalamic neurons that project to the spinal cord. J Comp Neurol 433, 222–238, 2001. He M

Open access

Farhat Batool, Ambreen Hasnat, Muhammad Haleem and Darakhshan Haleem

References S. Miyamoto, G. E. Duncan, C. E. Marx and J. A. Lieberman, Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs, Mol. Psychiatry   10 (2005) 79-104; DOI: 10.1038/sj.mp.4001556. S. Natesan, G. E. Reckless, K. B. Barlow, J. N. Nobrega and S. Kapur, Amisulpride the ‘atypical’ atypical antipsychotic-comparison to haloperidol, risperidone and clozapine, Schizophr. Res.   105 (2008) 224-235; DOI: 10.1016/j.schres.2008

Open access

Matej Štuhec, Demetrij Petrica and Janez Toni

patients with negative symptoms. Schizophr Res 2009; 113: 56-64. 16. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007; 90:147-161. 17. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito GG, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen

Open access

Osot Nerapusee, Chanadda Chinthammit, Chavalit Romyen, Maneeporn Pangjunhom, Daniel C. Malone and Rungpetch Sakulbumrungsil

), paliperidone palmitate (paliperidone), and risperidone LAI (risperidone). Currently, no direct evidence associated with the comparability of the efficacy of the 6 LAIs has been published. Those data are necessary not only for supporting the healthcare profession’s product selection for their patients, but also for supporting their cost effectiveness analysis. When there are many treatments available, but they have not been compared in a head-to-head manner, systematic reviews and mixed treatment comparison meta-analysis can be used to compare multiple products [ 17 - 19

Open access

Aneta Gerhant, Maciej Słotwiński, Olga Hołownia, Ewa Stelmach and Marcin Olajossy

, Rudd R, Quek J, Herbert P, McKinley M. Treatment of psychogenic polydipsia: comparison of risperidone and olanzapine, and the effects of an adjunctive angiotensin-II receptor blocking drug (irbesartan). Aust N Z J Psychiatry.2001;35(1):65-68. 56. Webber MA, Ofalabi I, Mahmud W, Herron MS, Shekhar A. Losartan for treatment of psychogenic polydipsia. Ann Pharmacother. 2004;38(10):1750-1751. 57. Dong HS, Kim SH, Park SY. A Case Report: Irbesartan and Naltrexone Treatment of Polydipsia in a Patient with Schizophrenia. Korean J Schizophr Res.2015

Open access

Elizabeta Mukaetova-Ladinska, Joaquim da Silva and Jon Darley

to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res. 2010;116(2-3):101-6. doi:10.1016/j.schres.2009.11.008 PMID:19959338. Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, Malloy H, Rowland C, Monkhouse A, Monkhouse A, Bole F, Sathiyamoorthy S, Piskulic D, Dodd S. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol. 2009;24(3):233-8. doi:10

Open access

Lukasz Zadka

References 1. Bissada H. et al.: Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry, 165, 10,2008. 2. Court A. et al.: Investigating the effectiveness, safety and tolerability of quetiapine in the treatment of anorexia nervosa in young people: a pilot study. J Psychiatr Res., 44, 15, 2010. 3. Hagman J. et al.: A double-blind, placebo-controlled study of risperidone for the treatment of